Study of mepartricin possible interactions with antilipemic drugs. Controlled clinical trials in patients with benign prostatic hyperplasia.
In order to more throughly study mepartricin pharmacodynamic characteristics, 2 groups of 15 patients with BPH and coexistent lipid metabolism disorders were studied in conformity with a sequential experimental design during which also systemic-acting (procetofen) and endoluminal-acting (cholestyramine) fat-lowering drugs were tried. The data obtained confirmed mepartricin specific effect on symptomatology and function in BPH and demonstrated the absence of positive and/or negative pharmacological interactions between the substance in question and the fat-lowering agents tried.
Piccinno
A
A
Cattedra di Urologia, Università degli Studi, Bari, Italy.
Cirillo Marucco
E
E
Ludovico
G M
GM
Pagliarulo
A
A
D000368:Aged; D004347:Drug Interactions; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008297:Male; D008613:Mepartricin / Q000008:administration & dosage*; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*
D000960:Hypolipidemic Agents; D008613:Mepartricin